Search & Analyze

Biocon Ltd.

HealthcarePharmaceuticals & Drugs

www.biocon.com BSE: 532523NSE: BIOCON

₹326.60BSE0.96%

23 Oct, 4:01 PM

₹326.60

₹53.23K Cr

107.46

1.57

1.35%

₹331.15

₹318.50

₹447.00

₹318.50

Customise metrics bar

Biocon Ltd. (BIOCON) share price closed at ₹326.60 on the BSE on Friday, October 23, 2026, down by 0.96% from its of ₹329.75. In that session BIOCON reached a of 331.15 and of 318.50. The for the session was 323.03. The stands at 384.14 and is at 391.83. Looking at , the stock ended the session moving sideways.

Stock Overview

Symbol

BIOCON

₹331.15

₹329.75

₹323.03

₹384.14

Price 14.98% below

₹391.83

Price 16.65% below

64.03% of range

₹318.50₹331.15

6.30% of range

₹318.50₹447.00

Price Performance

Peer Comparison

Name
SUN PHARMA. SUNPHARMA	1,743.00	34.58	4,18,204.09	0.92	2,901.23	26.53%	15,299.88	10.46%	19.11
DIVI'S LAB. DIVISLAB	8,984.00	81.54	2,38,496.97	0.33	902.00	65.50%	3,080.00	27.80%	21.51
TORRENT PHAR TORNTPHARM	4,482.00	80.26	1,70,480.87	0.85	534.00	-9.64%	4,979.00	50.79%	19.27
ZYDUSLIFE ZYDUSLIFE	1,127.85	24.93	1,12,503.47	0.09	990.20	-34.90%	8,017.00	21.96%	21.39
CIPLA LTD. CIPLA	1,337.00	32.04	1,08,012.30	0.97	785.55	-39.18%	7,119.28	2.33%	16.00
LAURUSLABS LAURUSLABS	1,974.00	97.55	1,06,657.63	0.10	362.07	123.94%	2,026.31	29.10%	18.20
DR.REDDY'S DRREDDY	1,224.50	36.50	1,02,206.60	0.65	913.20	-31.69%	8,697.80	-1.48%	13.75
Biocon Ltd. BIOCON	326.60	107.46	53,225.81	0.15	136.80	53.36%	4,336.00	10.00%	3.26

Quarterly Results

consolidated figures in ₹ Crores · Quarterly

Particulars	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
	3,432.90	3,590.40	3,821.40	4,417.00	3,941.90	4,295.50	4,173.00	4,516.60	4,336.00
Expenses	2,812.50	2,905.00	3,069.60	3,338.80	3,175.80	3,460.10	3,339.50	3,496.30	3,488.80
	620.40	685.40	751.80	1,078.20	766.10	835.40	833.50	1,020.30	847.20
	18.07%	19.09%	19.67%	24.41%	19.43%	19.45%	19.97%	22.59%	19.54%
	1,166.50	58.50	52.90	57.30	62.50	81.10	-176.10	-27.90	41.00
Interest	236.00	225.60	223.40	212.40	276.70	272.20	209.90	231.50	213.20
	405.40	419.90	425.40	436.30	455.00	473.00	515.30	513.40	547.40
	1,145.50	98.40	155.90	486.80	96.90	171.30	-67.80	247.50	127.60
	24.77%	72.46%	47.98%	5.63%	7.95%	22.48%	23.60%	19.76%	-7.21%
	659.70	-16.00	25.10	344.50	31.40	84.50	143.80	125.90	141.10
	5.49	-0.13	0.21	2.87	0.23	0.63	1.08	0.78	0.87

Profit & Loss

consolidated figures in ₹ Crores · Annual

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
INCOME :
	8,208.20	11,276.70	14,929.00	15,338.80	17,030.40
	8,184.00	11,174.20	14,755.70	15,261.70	16,927.00
EXPENDITURE :
Increase/Decrease in Stock	-256.60	-154.10	-856.70	294.20	-949.50
Raw Material Consumed	2,975.00	3,817.20	5,754.60	4,903.30	6,640.20
Power & Fuel Cost	316.40	414.80	388.90	377.90	426.40
Employee Cost	1,880.10	2,181.00	2,664.10	3,144.40	3,508.00
Other Manufacturing Expenses	1,243.50	1,917.20	2,376.90	1,655.90	1,796.20
General and Administration Expenses	181.50	359.60	806.00	948.10	1,065.90
Selling and Distribution Expenses	243.80	221.60	296.60	649.90	698.80
Miscellaneous Expenses	107.70	297.40	128.60	269.30	399.40
	6,691.40	9,054.70	11,559.00	12,243.00	13,585.40
Operating Profit (Excl OI)	1,492.60	2,119.50	3,196.70	3,018.70	3,341.60
	690.30	768.10	967.50	1,355.80	456.20
	2,182.90	2,887.60	4,164.20	4,374.50	3,797.80
Interest	67.60	419.00	974.40	897.40	990.30
PBDT	2,115.30	2,468.60	3,189.80	3,477.10	2,807.50
	814.20	1,113.10	1,568.80	1,687.00	1,956.70
Profit Before Taxation & Exceptional Items	1,301.10	1,355.50	1,621.00	1,790.10	850.80
Exceptional Income / Expenses	-111.10	-291.40	-11.60	96.50	-402.90
	983.10	897.10	1,525.20	1,886.60	447.90
Provision for Tax	211.50	254.10	227.40	457.20	79.10
	771.60	643.00	1,297.80	1,429.40	368.80
Extra items				0.00	0.00
Minority Interest	-123.20	-180.30	-275.30	-416.10	16.80
Consolidated Net Profit	648.40	462.70	1,022.50	1,013.30	385.60
Profit Balance B/F	6,235.80	6,827.30	16,085.90	17,602.80	18,959.10
Appropriations	6,884.20	7,290.00	17,108.40	18,616.10	19,344.70
Equity Dividend %	10.00%	30.00%	10.00%	10.00%	10.00%
	5.40	3.85	8.52	8.44	2.38
Adjusted EPS	5.40	3.85	8.52	8.44	2.38

Balance Sheet

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
	600.30	600.30	600.30	600.30	810.50
Share Warrants & Outstandings	204.10	274.00	320.10	424.90	514.30
Total Reserves	7,628.10	16,992.60	18,863.30	20,618.80	32,707.00
Reserve excluding Revaluation Reserve	7,627.20	16,991.70	18,862.40	20,617.90	32,706.10
Revaluation reserve	0.90	0.90	0.90	0.90	0.90
	8,432.50	17,866.90	19,783.70	21,644.00	34,031.80
Minority Interest	1,037.50	4,621.90	5,491.10	6,068.50	2,589.70
Secured Loans	2,574.30	13,692.30	11,267.70	10,502.50	10,476.30
Unsecured Loans	1,424.20	1,598.20	1,664.70	1,902.90	270.00
Deferred Tax Assets / Liabilities	-241.00	80.80	74.20	100.00	-313.90
Other Long Term Liabilities	2,953.50	5,144.50	1,875.60	3,727.10	1,641.60
Long Term Provisions	91.70	226.50	237.60	260.80	330.30
Total Non-Current Liabilities	6,802.70	20,742.30	15,119.80	16,493.30	12,404.30
Trade Payables	1,608.50	3,842.00	6,272.00	6,548.70	6,772.10
Other Current Liabilities	1,031.20	1,814.90	6,481.20	3,965.70	3,059.30
Short Term Borrowings	896.00	2,480.20	2,149.20	3,454.70	3,566.30
Short Term Provisions	292.30	373.60	456.40	364.70	671.50
Total Current Liabilities	3,828.00	8,510.70	15,358.80	14,333.80	14,069.20
Total Liabilities	20,100.70	51,741.80	55,753.40	58,539.60	63,095.00
Gross Block	11,233.00	35,321.40	37,930.10	40,804.30	48,079.20
Less: Accumulated Depreciation	4,664.00	5,853.70	7,286.50	8,841.00	11,593.30
Net Block	6,569.00	29,467.70	30,643.60	31,963.30	36,485.90
Capital Work in Progress	3,420.30	2,587.50	3,985.20	4,101.70	4,612.70
Non Current Investments	370.20	742.30	684.10	679.70	1,089.30
Long Term Investment	370.20	742.30	684.10	679.70	1,089.30
Long Term Loans & Advances	483.80	683.20	892.50	870.80	973.80
Other Non Current Assets	185.00	1,197.60	360.70	231.20	379.50
Total Non-Current Assets	11,718.40	39,407.80	40,574.20	42,253.40	45,915.20
Currents Investments	1,217.70	1,326.50	315.60	447.30	689.80
Inventories	2,298.20	4,243.70	4,943.90	4,931.10	6,085.70
Sundry Debtors	2,058.20	3,573.20	6,230.60	5,487.90	5,986.80
Cash and Bank	1,747.50	2,400.10	2,258.70	4,120.20	3,193.60
Other Current Assets	660.20	334.10	334.40	382.70	419.20
Short Term Loans and Advances	400.50	456.40	1,096.00	917.00	804.70
Total Current Assets	8,382.30	12,334.00	15,179.20	16,286.20	17,179.80
Net Current Assets (Including Current Investments)	4,554.30	3,823.30	-179.60	1,952.40	3,110.60
Total Assets	20,100.70	51,741.80	55,753.40	58,539.60	63,095.00
Contingent Liabilities	844.40	947.80	1,135.60	1,176.10	928.40
Total Debt	4,904.00	17,770.70	15,729.60	17,755.50	14,824.70
	68.53	146.53	162.11	176.73	206.77
Adjusted Book Value	68.53	146.53	162.11	176.73	206.77

Cash Flow

consolidated figures in ₹ Crores

Particulars	FY 2021-22 (Mar)	FY 2022-23 (Mar)	FY 2023-24 (Mar)	FY 2024-25 (Mar)	FY 2025-26 (Mar)
No of Months	12.00	12.00	12.00	12.00	12.00
	983.10	897.10	1,525.20	1,886.60	447.90
Adjustment	1,245.00	1,685.00	2,356.20	1,711.20	2,920.90
Changes In working Capital	-789.50	-501.00	-635.20	923.00	-1,132.20
Cash Flow after changes in Working Capital	1,438.60	2,081.10	3,246.20	4,520.80	2,236.60
Cash Flow from Operating Activities	1,176.60	1,852.50	2,953.90	4,061.20	1,994.00
Cash Flow from Investing Activities	-1,699.10	-14,281.80	-1,004.50	-234.10	-2,082.10
Cash Flow from Financing Activitie	242.10	13,048.70	-2,332.70	-1,854.00	-923.60
Net Cash Inflow / Outflow	-280.40	619.40	-383.30	1,973.10	-1,011.70
Opening Cash & Cash Equivalents	897.00	653.70	1,299.90	919.50	2,923.80
Cash & Cash Equivalent on Amalgamation / Take over / Merger	33.80
Effect of Foreign Exchange Fluctuations	3.30	21.70	2.90	31.20	199.40
Closing Cash & Cash Equivalent	653.70	1,294.80	919.50	2,923.80	2,111.50

Ratios

Valuation

107.46

1.57

16.83

3.10

3.04

208.53

Profitability

1.35

3.26

0.61

19.62

2.17

Leverage & Liquidity

0.44

1.22

1.45

Returns

0.15

0.28

Shareholding Pattern

Numbers in percentages

Particulars	Jun '24	Sep '24	Dec '24	Mar '25	Jun '25	Sep '25	Dec '25	Mar '26	Jun '26	Sep '26
	60.64	60.64	60.64	60.64	54.45	54.45	54.45	44.91	44.68	44.68
	20.20	20.37	21.02	21.38	28.86	28.71	29.10	31.59	31.52	37.94
	19.17	18.99	18.34	17.97	16.68	16.83	16.45	23.49	23.80	17.39
	39.36	39.36	39.36	39.36	45.55	45.55	45.55	55.09	55.32	55.32
No. of Shareholders	4,43,513	4,39,503	4,27,705	4,24,297	4,28,131	4,13,191	3,94,279	3,86,593	3,92,833	3,93,051

Mutual Funds Invested(225)

Based on each fund's latest monthly portfolio · Sep 2026

A total of 147 active funds hold 21.66% in Biocon Ltd., contributing to ₹13.07K Cr of holdings

Fund				As of
SB SBI Contra Fund - Growth - Direct PlanEquity - Contra Fund	1,483.94	3.29	4,00,73,925	Sep '26
SB SBI Large & Midcap Fund - Growth - Direct PlanLarge & Mid Cap	892.42	2.20	2,41,00,000	Sep '26
KO Kotak Mid Cap Fund - Growth - Direct PlanMid Cap Fund	687.36	1.03	1,85,62,250	Sep '26
SB SBI Midcap Fund - Growth - Direct PlanMid Cap Fund	577.62	2.48	1,55,98,584	Sep '26
SB SBI Balanced Advantage Fund - Growth - Direct PlanHybrid - Balanced Advantage	482.18	1.19	1,30,21,205	Sep '26
KO Kotak Large & Mid Cap Fund - Growth - Direct PlanLarge & Mid Cap	481.39	1.57	1,30,00,000	Sep '26
IP ICICI Prudential Focused Fund - Growth - Direct PlanEquity - Focused Fund	461.48	2.69	1,24,62,450	Sep '26
SB SBI Multicap Fund - Growth - Direct PlanMulti Cap Fund	408.19	1.74	1,10,23,314	Sep '26
IP ICICI Prudential Healthcare Fund - Growth - Direct PlanPharma & Health Care	365.74	5.33	98,76,830	Sep '26
IP ICICI Prudential Multi Asset Allocation Fund - Growth - Direct PlanHybrid - Multi Asset Allocation	320.17	0.38	86,46,221	Sep '26

Corporate Actions

Showing: All

Date	Type	Details	Ex-Date	Record Date
2026-07-28	Board Meeting	Quarterly Results
2026-07-15	AGM
2026-05-08	Ex Dividend	Rs.0.5000 per share(10%)Final Dividend	2026-07-03	2026-07-03

Insider Trading

Date	Person	Category	Transaction Type	Shares	Value (₹)

No insider trading data available.

Sector Overview

HealthcarePharmaceuticals & Drugs

Biocon Ltd. operates in the Healthcare sector under the Pharmaceuticals & Drugs industry. This sector is one of the key drivers of the Indian economy and is closely tracked by the relevant Nifty sectoral index.

Company Profile

Corporate information and contact details

Key Management

17 members across the board and senior leadership

Rajesh Shanoy

Company Secretary & Compliance Officer

—

Kiran Mazumdar-Shaw

Chairperson

₹5.50 Cr

Mar '26

Shreehas Pradeep Tambe

Managing Director & CEO

—

Ravi Rasendra Mazumdar

Non Independent & Non Executive Director

₹79.00 L

Mar '26

Eric Vivek Mazumdar

Non Independent & Non Executive Director

₹66.80 L

Mar '26

Naina Lal Kidwai

Non Executive Independent Director

₹1.02 Cr

Mar '26

Bobby Kanubhai Parikh

Non Executive Independent Director

₹83.30 L

Mar '25

Rekha Mehrotra Menon

Non Executive Independent Director

₹79.90 L

Mar '26

Rajiv Malik

Independent Director

—

Nicholas Robert Haggar

Non Executive Independent Director

₹80.50 L

Mar '26

Atul Dhawan

Non Executive Independent Director

₹74.00 L

Mar '26

Rajesh Umakant Shanoy

Company Secretary and Compliance Officer

—

Daniel Bradbury

Independent Director

—

Arun Suresh Chandavarkar

Independent Director

—

Nivruti Rai

Independent Director

—

Thomas Jason Roberts

Non Independent & Non Executive Director

—

Peter Baron Piot

Independent Director

—

BIOCON Latest News

News

10 of 10 articles

EQUITY14 Oct 2026 · 09:36

Biocon informs about company statement

EQUITY25 Sept 2026 · 11:02

Biocon informs about company statement

EQUITY21 Sept 2026 · 09:25

Biocon informs about press release

EQUITY8 Sept 2026 · 10:05

Biocon informs about press release

EQUITY8 Sept 2026 · 09:41

Biocon moves up on securing supply contract for Pertuzumab in Brazil

The consortium of Biocon, Bahiafarma and Bionovis received 100% allocation under Brazil's 10-year PDP program for Pertuzumab

COMPANY8 Sept 2026 · 09:17

Biocon secures supply contract for Pertuzumab in Brazil

The consortium of Biocon, Bahiafarma and Bionovis received 100% allocation under Brazil's 10-year PDP program for Pertuzumab

COMPANY25 Aug 2026 · 10:47

Biocon’s arm secures marketing approval for pegfilgrastim biosimilar in Japan

This approval further strengthens the company’s portfolio of biosimilar products in Japan

EQUITY25 Aug 2026 · 09:23

Biocon informs about company statement

EQUITY18 Aug 2026 · 11:39

Biocon informs about disclosure

EQUITY6 Aug 2026 · 11:37

Biocon surges on reporting over 4-fold jump in Q1 consolidated net profit

The total consolidated income of the company has increased by 9.17% at Rs 4,390.50 crore for Q1FY27

BIOCON

₹326.60

-0.96%